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Abstract 
 
Purpose of Review: The management of patients suffering from low-grade 
gliomas (LGG) remains a challenge in absence of a definite curative therapy. 
The median survival is highly variable, from 2 (high-risk disease) to over 15 
years (low risk). The aim of this review is to provide a practical step by step 
evaluation of the patients and of the available treatment options. 
Recent findings: Next to clinical prognostic markers, both the IDH mutation 
status and the status of 1p/19q codeletion are key prognostic factors for the 
optimal management of patients with LGG. Two recent randomized phase III 
clinical trials were performed in LGGs. The first compared the efficacy of 
radiation (RT) versus temozolomide chemotherapy in high risk LGGs. The 
second trial compared RT versus RT combined with PCV chemotherapy. 
Summary: Regarding molecular prognostic factors IDH wild type LGG have 
the worst prognosis, independent of therapy, while patients with mutated IDH, 
codeleted 1p/19q LGGs fared best regarding progression-free survival. In high 
risk LGGs PFS is similar regardless of whether patients have been treated 
with RT or TMZ. In the second trial, patients that were treated with 
combination RT and chemotherapy showed significant longer overall survival.  
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Introduction  
 
Diffusely infiltrating gliomas are primary tumors of the central nervous system 
(CNS) that are classified into distinct entities based on the histopathological 
resemblance (phenotype) of the tumor cells and the genotype. According to 
the revised fourth edition of the WHO classification[1] these comprise 3 major 
subtypes, diffuse astrocytoma with mutation of the isocitrate dehydrogenase 
gene 1 or 2 (IDH1, IDH2; IDHmt), astrocytoma IDH wildtype (wt), and 
oligodendroglioma IDH mutant, and co-deleted for chromosomal arms 1p 
and19q (1p/19q codeleted); or in absence of genetic information into 
astrocytoma or oligodendroglioma not otherwise specified (NOS), respectively 
(FIGURE 1) 
 
The median age of patients diagnosed with LGGs typically ranges from the 
late twenties to the mid forties, although some patients may be diagnosed 
after 60 years of age[2]. They are therefore relatively younger than patients 
diagnosed with an anaplastic astrocytoma or glioblastoma. The majority of 
patients present with seizures, sometimes that may have gone unrecognized 
for years. Given the widespread use of CT or MRI, an increasing number of 
patients are diagnosed with a suspected glioma for unrelated symptoms such 
as vertigo, migraine or head trauma. The appearance of a LGG is usually 
quite typical on MRI (FIGURE 2). Over 95% of them present in a 
supratentorial localization and appear hypointense on T1 without uptake of 
contrast in most cases and hyperintense on T2/FLAIR. Susceptibility-weigthed 
sequences may show calcifications. The center of the lesion is usually 
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localized in the white matter, although oligodendrogliomas may infiltrate or 
expand into the cortex[3]. 
 
Prognostic molecular markers 
Recent advances in molecular characterization of gliomas have provided 
insights into their etiologic evolution, which is reflected in part in the new WHO 
classification (FIGURE 3)[1]. Mutation of IDH1 or 2 is the hallmark of diffuse 
astrocytoma and oligodendroglima and has been associated with better 
outcome as opposed to IDHwt astrocytoma[4]. The most commonly identified 
mutant is IDH1 R132H, which represents >90% of all IDH1 and 2 mutations 
and can be readily identified by immunohistochemistry[5]. Negative cases 
need to be subjected to sequence analyses of both IDH1 and 2. The 
mutations identified are gain of function mutations that alter the normal 
catalytic activity of the enzyme to produce 2-hydroxyglutarate, which 
accumulates to high concentrations in the tumors. This oncometabolite 
inhibits α-ketoglutarate dependent enzymes, including TET2 that is involved 
in DNA demethylation[6]. Thereby IDH mutants seem to mediate the formation 
of a CpG island methylation phenotype (CIMP)[7], associated with broad 
alteration of gene expression, resulting from silencing of genes including 
cancer relevant tumor suppressor genes. 
 
The combined loss of one copy of chromosome arms 1p and 19q occurs in 
IDHmt tumors and is the hallmark of oligodendroglial tumors. This results from 
an unbalanced whole-arm translocation between chromosomes 1 and 19 with 
loss of the derivative chromosome t(1p:19q) and has been associated with 
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sensitivity to chemotherapy[8]. IDHmt and 1p/19q codeleted tumors are usually 
associated with TERT promoter mutations associated to increased 
expression, while the non-codeleted IDHmt tumors are associated with TP53 
mutations and mutations of alpha thalassemia/mental retardation syndrome X 
linked gene (ATRX). The latter can be assessed as loss of ATRX expression 
by immunohistochemistry[9]. Both TERT and ATRX are involved in 
maintenance of telomeres, which may drive the development of all gliomas[10]. 
 
In LGGs, the role of the methylation status of the repair gene O6-methyl-
guanine-DNA methyltransferase (MGMT) is quite different from GBMs, where 
it is a known predictive factor for benefit from alkylating agent therapy[11]: 
IDHmt or CIMP+ tumors are highly associated with MGMT methylation, being 
positive in 100% of the 1p/19q codeleted LGGs and over 90% of the non-
codeleted cases; In contrast, among IDHwt/CIMP- LGGs, only 40% were 
MGMT methylated[12, 13] (FIGURE 3). In other words, due to the nested 
relationship, the determination of the MGMT methylation status in 
IDHmt/CIMP+ tumors does not provide additional information. Furthermore, in 
contrast to GBM that loose the second allele of MGMT due to the common 
deletion of chromosome 10 (10q26 location of MGMT), in IDHmt gliomas a 
second allele is present, and residual MGMT expression may be expected, 
blunting the treatment effect even in MGMT methylated cases[13].  
 
These retrospective observations have been confirmed in an international 
prospective randomized trial in patients with LGG (EORTC 22033-26033) 
where patients with IDHwt tumors had the worst prognosis, independent of 
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therapy, while patients with IDHmt/1p/19q codel tumors fared best regarding 
progression-free survival[14]. It is important to note that tumor grade has little 
impact on the outcome of patients with IDHmt tumors[15]. Although, this may 
be confounded by different initial treatment attitudes, as reported by Weller et 
al. where 90% of the patients with grade III tumors received immediate 
treatment in contrast to only 10% of grade II patients being treated 
immediately at diagnosis[16]. In contrast, in IDHwt LGGs, grade and age play 
an important role[17-19]. However, this subgroup is ill defined. Upon further 
molecular analysis most IDHwt astrocytoma may be classified as GBM, 
although this group also comprises less malignant tumors such as pilocytic 
astrocytoma[15, 20]  
 
Management of patients with low grade gliomas 
Clinical prognostic factors 
The outcome of patients with LGGs may be extremely variable, spanning from 
as little as 2 years to over 15 years[21]. The identification of prognostic factors 
is thus critical for the optimal management of the patient. A prognostic score 
is available to help identifying patients being at risk for progression and thus 
needing a therapy. This score is derived from two large randomized EORTC 
studies[22]. In multivariate analysis, age ≥ 40 years, astrocytic tumour type, 
tumor size > 6 cm, tumor crossing the midline, and neurological deficit at 
diagnosis (before surgery) were identified as prognostic factors. A favorable 
(low-risk) prognostic score (< 2 factors present) was associated with a median 
survival of 7.7 years (95%CI=6.6-9.3). The presence of three to five 
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prognostic factors was associated with a median survival of 3.2 years 
(95%CI:3.0-4.0)[22]. More recently, this score was refined based on data from 
randomized trials from the EORTC and North American cooperative groups. 
Both PFS and OS were negatively influenced by the presence of baseline 
neurological deficits, a shorter time since first symptoms, an astrocytic tumor 
type, and tumors larger than 5 cm in diameter. In this more homogeneously 
defined patient population three risk groups were identified (low, intermediate, 
and high risk)[23]. 
 
1. Observation vs surgery 
Once a lesion compatible with a LGG is identified on MR imaging, it should be 
decided whether to intervene surgically, and if so, whether to perform a biopsy 
or a resection. In certain situations, this decision might be quite easy: for 
instance in a patient that presents a small, easily resectable lesion or if the 
patient presents with neurologic deficits or has a significant mass effect. On 
the opposite, the decision is more difficult in a patient with an incidentally 
detected lesion or well-controlled seizures. To date, regarding outcome, there 
is no compelling evidence that early intervention is superior to observation 
with surgery reserved for the time point when the lesion grows. It must 
however be noted that LGGs grow continuously[24] and up to 50% of 
anaplastic gliomas do not enhance and can therefore not be distinguished 
from lower grade tumors. In this decision, not only patient preference, but also 
a number of prognostic factors must factored in as age, tumor size, location 
and surgical risks (see above). Imaging with FET-PET might represent an 
additional tool to help identify tumors that have a more aggressive 
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behavior[25]. If observation is selected, the patient must be carefully followed 
with serial MRIs and neurological observation. As soon as the tumor shows 
significant growth, signs of transformation or significant neurological deficits a 
definite diagnosis must be established. It is essential that the time point where 
a surgical resection is no longer feasible is not missed.  
 
2. Biopsy versus surgery 
Once the decision to obtain a definitive diagnosis has been reached, it must 
be decided whether to aim for a resection or a biopsy. It is obvious that larger 
resections minimize the risk of misdiagnosis or diagnosis to a lower level of 
aggessivity linked to the potential miss-sampling of a biopsy sample taken in a 
heteregenous tumor[26]. Regarding outcome, there is however no class I 
evidence available to differentiate between biopsy or resection. Several 
retrospective studies have tried to compare them. For instance, a 
retrospective review of 216 patients showed that the extent of resection 
correlated significantly with overall survival: patients that had >=90% resection 
showed a 5-year survival of >97%, versus 76% in those with larger residual 
tumors[27]. Similarly, another study showed a 5-year OS of 97% in patients 
with complete resection versus 70% if incomplete[28]. A Norwegian population-
based parallel cohort study showed an improved overall survival in patients 
undergoing maximal safe resection versus those having undergone biopsy[29]. 
These retrospective studies are however likely to be biased by a number of 
factors, including smaller tumors, better localization, better performance 
scores for patients with more aggressive resections and a potential lead in 
bias as different doctors may decide differently at which time point treatment 
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must be started. Some studies have indeed found that although extensive 
resection predicts better outcome in univariate analysis, this finding is lost on 
multivariate analysis once data are controlled for other prognostic factors[22].  
 
Practically, the general consensus is to recommend a maximal safe resection 
whenever possible. In cases where only a small portion of the tumor might be 
amenable to resection, a FET-PET scan may help to identify the most 
aggressive parts of the tumor that will be the ideal location for biopsy or for 
partial resection[25].  
 
Postoperative management 
Once the diagnosis is established, the optimal management of patients with 
LGGs remains challenging and controversial, as neither the time, nor 
sequence of treatment has been unambiguously resolved. A number of issues 
should be addressed, ideally in the setting of a multidisciplinary tumor board. 
 
Postoperative follow-up? 
The first question that usually arises is whether patients may be followed 
postoperatively without immediate postoperative treatment. This approach 
was mainly supported by the results of the randomized phase III 
EORTC22845 study that evaluated immediate postoperative radiotherapy 
versus delaying radiotherapy to the time point of progression in 157 patients 
with low grade astrocytoma and oligodendrogliomas. Whereas patients that 
underwent early RT had longer PFS, OS was similar in both groups[30]. This 
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option should be reserved for patients that underwent excellent resections 
and show no negative prognostic factors (age <=40, small initial tumor 
volume, absence of neurological deficit, and presence of favorable prognostic 
molecular markers (IDHmt, ideally 1p/19q codeleted). These patients will 
however need careful long-term surveillance with serial MRIs. Moreover 
comparisons will have to be made with the postoperative MRI. Indeed, it must 
be noted that in a prospective study 50% of patients with LGGs less than 40 
years old that had undergone complete radiological resection, 50% showed 
disease progression 5 years after surgery[31].  
 
Radiation therapy? 
Patients being at a high risk to recurrence or progression (patients older than 
40 years, after incomplete resection, with unresectable tumors or neurologic 
symptoms) are usually treated with radiation therapy. Radiotherapy is usually 
given in daily fractions of 1.8-2 Gy to a total dose of 45-50.4 Gy. Two 
randomized trials investigating radiation doses found no difference in overall 
survival for higher doses when comparing 45 Gy and 59.4 Gy, and 50.4 Gy 
and 64.8 Gy, respectively[32, 33]. However, toxicity is significantly worse with 
higher radiation dose levels: A 2-year actuarial incidence of grade ≥ 3 
radiation necrosis of 2.5% has been observed in patients treated with a total 
dose of 50.4 Gy versus a 5% rate using 64.8 Gy[30, 32]. Approximately 30% of 
patients treated with RT will show tumor shrinkage. Of particular concern in 
patients with LGG is the development of long-term neurocognitive deficits. In 
a study of 195 patients with LGGs followed at a mean of 12 years after 
diagnosis showed that patients that had received no RT had stable 
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radiological and neurocognitive status, whereas patients that had undergone 
RT showed progressive neurocognitive decline associated with radiologic RT 
induced leukoencephalopathy[34]. The risk of long-term neurocognitive deficit 
must therefore be considered carefully for these patients, especially those 
with the longest expected outcomes (oligodendrogliomas IDHmt, 1p/19q 
codeleted), although most recent studies evaluating long term effects of 
radiation therapy suggest that there is only sporadic limited, neurocognitive 
damage from focal radiotherapy at the usually prescribed doses for low-grade 
gliomas[35]. 
 
In the EORTC 22844 trial, functioning concerning quality-of-life was lower for 
patients who received 54Gy compared to 45Gy in the EORTC22844 trial 
especially for fatigue, insomnia and emotional functioning[36], however, there 
was no difference in quality-of-live scales in the randomized EORTC 22033 
trial between patients treated with RT or TMZ, although the follow up remains 
limited in this study[37].   
 
It must be noted that following RT, determining further tumor progression 
might be challenging as RT may cause delayed white matter changes that 
may resemble tumor progression. The RANO group has devised a 
radiological assessment tool to assist in this evaluation[38]. 
 
Chemotherapy? 
Given the risks associated with RT, using chemotherapy as a first line 
treatment option has been widely evaluated. This approach was further 
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validated by the observation that anaplastic and grade II oligodendrogliomas 
with 1p/19q codeletion were highly sensitive to chemotherapy[8]. These early 
studies were performed with a combination of procarbazine, lomustine and 
vincristine (PCV). This combination was then replaced by temozolomide as 
this agent showed a much better tolerability and fewer side effects. A number 
of small phase II studies showed similar response rates and OS than RT, 
typically in the range of 3-5 years[39]. To validate these findings, the EORTC 
launched a large phase III trial to randomize 477 patients with low grade 
gliomas and a high risk profile (defined as age>40, neurologic deficits or 
progredient lesions under supervision) between 12 cycles of temozolomide or 
standard RT (EORTC 22033)[14]. After a median follow up of 4 years there 
was no difference between the two modalities for PFS, with a median PFS of 
39 months for patients treated with TMZ (CI95: 35-44 months) and 46 months 
(CI95: 40-56 months; HR for progression: 1.16 (CI95: 0.9-1.5); p=0.22) in the 
RT-arm. The data are not yet mature enough to evaluate OS. Molecular 
subgroup analyses suggest that for patients with IDHmt, 1p/19q codeleted 
tumors no difference was observed in PFS between TMZ and RT. Treatment 
with chemotherapy first would allow delay of RT and its associated risks for 
long term CNS toxicity. However, patients with IDHmt 1p/19q non-codeleted 
tumors showed significantly longer PFS when treated with RT as compared to 
temozolomide[14].  
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Combination of chemotherapy and radiation therapy? 
The combination of radiation therapy and chemotherapy has resulted in 
significantly improved outcomes in glioblastoma[40] and anaplastic 
oligodendrogliomas with 1p/19q codeletions[41, 42].  
 
In a randomized phase III trial, 251 patients with high risk LGG, defined as 
less than complete resection or that were >=40 at age of diagnosis were 
randomized to receive either RT alone or RT followed by PCV chemotherapy. 
The study was started in 1998. Preliminary results published in 2012 showed 
no survival advantage with the addition of chemotherapy[43]. A subsequent 
analysis with longer follow up showed a significant survival advantage for 
patients that were treated with the combination treatment (13.3 vs 7.8 
years)[44]. Unfortunately, this study only provides incomplete information about 
the molecular status of the patients, as information about IDH1 R132H status 
was available for 60% of patients, but the 1p/19q codeletion status has not 
been evaluated. Hence, it remains difficult to determine which molecular 
subgroup of patients particularly benefits from this combination of treatments, 
especially as 2 large trials in grade III gliomas (high grade) showed no 
evidence for increased survival in patients that did not present the 1p/19q 
codeletion[42, 45]. Nevertheless, in absence of additional data and given the 
large difference in OS observed in the latter study, it is probably safe to 
recommend the addition of chemotherapy in patients that are scheduled to 
undergo RT.  
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PCV chemotherapy is associated with quite severe side effects and only 56% 
of the patients were able to actually complete the planned cycles of PCV[44]. 
Thus it remains a valid question as to whether PCV can be replaced by TMZ, 
an alkylating agent that was developed after the initiation of this trial and that 
has a much better safety profile. Unfortunately there are no prospective data 
available to answer this question. It must however be noted that patients with 
anaplastic gliomas, the NOA-04 trial, who received either PCV or TMZ in the 
chemotherapy arm found that PCV was better than TMZ for PFS (HR: 0.39 
[95CI: 0.17-0.92]), although this was not an endpoint and the trial was not 
powered for this analysis[46], whereas Brada et al showed that patients with 
recurrent high grade gliomas showed identical outcomes whether treated with 
PCV or TMZ[47]. Based on these findings and the fact that TMZ is much better 
tolerated than PCV and that patients will be more likely to actually complete 
their planned treatment course, we feel that it is justified to propose the option 
of a combination treatment with RT and TMZ to patients after careful 
explanation of the available data.  
 
Conclusions 
As the life expectancy of LGGs is extremely variable with IDHmt tumors 
possibly with little growth over years whereas IDHwt tumors can grow faster 
and more aggressively, treatment of LGGs remains extremely challenging. As 
now implemented in the WHO classification, it is of high importance to 
determine both the IDH mutation status and the status of 1p/19q codeletion. 
These molecular markers should be part of the initial diagnostic workup for all 
patients with a LGG in order to define an individual treatment strategy. This 
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strategy is a careful balancing act between the selection of the right time point 
to start treatment, the choice of the optimal treatment and a careful risk 
assessment of the expected therapeutic efficacy of the treatment and its 
potential late term complications. In short: Initial observation may be a 
reasonable postoperative option in a subset of patients defined both by 
clinical and molecular factors. If it is decided that the patient must be treated, 
options include radiation therapy, chemotherapy or a combination of both. 
Recent data suggest that a combination of RT followed by chemotherapy is 
probably superior to RT alone. Further trials will be needed to fully establish 
the best treatment options. 
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Figure legends 
Figure 1  
New 2016 WHO classification of brain tumors: Integration of histopatologic 
features with tumor genetics. Adapted from [1] with permission. 
Figure 2 
Typical MRI sequence of a left frontal oligodendroglioma showing T2 
hyperintensity  
 
Figure 3 
Relationship of biomarkers in low grade glioma. The Venn diagram depicts 
the relationship of IDH mutations or CIMP status and coedeletion of 1p/19q 
and the MGMT methylation status in the low grade glioma cohort of the TCGA 
(N=206). Analyses were performed as described in Bady et al [13] (with 
permission). 
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Key points in the management of patients with low grade gliomas 
• The optimal management of low grade gliomas remains controversial. 
• To date, no compelling evidence demonstrates that early intervention 
with surgery improves outcome over observation in low grade gliomas. 
These patients must however be carefully followed with serial MRIs 
and comparisons must be made with the oldest MRI. 
• Once progression is established, maximal safe resection should be 
favored over biopsy. 
• Initial observation may be a reasonable postoperative option in a 
subset of patients defined both by clinical and molecular factors. These 
patients must however be carefully followed with serial MRIs. 
Comparisons should systematically be performed with the 
postoperative MRI. 
• If it is decided that the patient must be treated, options include radiation 
therapy, chemotherapy or a combination of both. Recent data suggest 
that a combination of RT followed by chemotherapy is probably 
superior to RT alone 
• The choice of treatment must include the assessment of clinical and 
molecular prognostic factors and a careful evaluation of potential late 
complications of the treatment 
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